Companies › Suzhou Forlong Biotechnology
1 active drug program in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| FL115 IL-15 agonist (IL-15[N72D]/IL-15Rα-sFc fusion protein) | IL15, IL15RA | Phase 1 | Locally Advanced/Metastatic Solid Tumors; Advanced Solid Tumors; Non-muscle Invasive Bladder Cancer (NMIBC) | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07131189 | FL115 | Phase 1 | Locally Advanced/Metastatic Solid Tumors | Oncology | Jun 2026 |
| NCT07131202 | FL115 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2026 |
| NCT07122414 | FL115 | Phase 1 | Non-muscle Invasive Bladder Cancer (NMIBC) | Oncology | Oct 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.